121. Mission-driven biotech investing, Josh Wolfe, Co-founder & Managing Partner, Lux Capital

It’s possible to identify a few patterns across these domains. First, VCs are investing in science much earlier than they have been comfortable with over the past two decades as software and the internet monopolized the limelight.

None of this bodes well for many of the new VC entrants who have suddenly become enamored by the capital return potential of science. We have a view that real advances in science are relatively rare, that they are hard to produce, and they tend to be signaled by clear research evidence years if not decades in advance. Venture capital is not a fit f... See more

Liron has formal training as a theoretical scientist and has founded 2 startups. The first one raised 170M and went to nothing. The second one, Relationship Hero, is currently at 6M revenue while profitable.

"We help companies build, survive, and scale, but one of the main components of my job is understanding how and when the world is going to change. Our portfolio is a collage of various futures that we believe in, and our capital and expertise are assets to hopefully pull these futures forward."